Dr. Caroline Elsner addressed personalized mRNA-based therapies for high-risk melanoma in a feature published on Oncodaily, joining a growing chorus of oncology researchers betting on tumor-specific vaccines as the next adjuvant lever in melanoma care. The Oncodaily piece, headlined "Caroline Elsner: Personalized mRNA-Based Therapies for High-Risk Melanoma," treats the topic as a clinician-facing conversation rather than a single-trial recap, and it lands at a moment when several mRNA melanoma programs are mid- or late-stage.

Why high-risk melanoma is the target cohort

High-risk melanoma — broadly, stage IIB and above disease with deep invasion, ulceration, or nodal involvement — remains the segment where adjuvant therapy shows the largest absolute survival lift and where residual unmet need is sharpest. Five-year recurrence rates after surgical resection exceed 40% in thick primaries and node-positive disease under AJCC 8th-edition staging, which keeps investigators focused on adjuvant intensification rather than treatment-naive first-line work.

mRNA platforms fit that gap because they compress the timeline from tumor sequencing to a patient-specific neoantigen set into weeks, then deliver those antigens as a lipid-encapsulated immunogen. The mechanism pairs naturally with checkpoint blockade, since the vaccine is meant to broaden T-cell recognition while PD-1 inhibitors release the brake on tumor-infiltrating lymphocytes.

Where the field sits in 2026

Three programs have carried the category into registrational territory:

• Moderna's mRNA-4157 (V940), combined with pembrolizumab, reported a 2.5-year recurrence-free survival benefit and a 49% reduction in recurrence or death risk versus pembrolizumab alone in resected stage III/IV melanoma at ASCO 2025, with a 49% RFS hazard ratio reported in earlier KEYNOTE-942 data.
• BioNTech's BNT122 (autogene cernumeran), partnered with Genentech/Roche, is in the phase 2 IMCODE-003 trial against standard-of-care adjuvant therapy.
• CureVac and Merck KGaA's CVGBM, a shared-antigen mRNA vaccine, is in earlier-stage development.

None has reached FDA or EMA approval for melanoma as of the latest cut, and the regulatory bar — a randomized survival endpoint in the adjuvant setting — is the bottleneck the category has yet to clear.

What Elsner brings to the conversation

Elsner, a German dermatologist and laser medicine specialist, has long worked at the intersection of dermatologic oncology and aesthetic dermatology, a hybrid practice that places her squarely inside the patient population mRNA melanoma vaccines are designed for. Her Oncodaily appearance slots her into a European clinician-commentary track that has, over the past 18 months, included dermatologist-investigators weighing in on neoantigen vaccines at meetings such as the EADO congress and the German Dermatology Society (DDG) annual meeting.

What readers should watch next

The next data drops that will move the field are the IMCODE-003 readout and any update to mRNA-4157's three-year landmark analysis, both expected in the next reporting cycle. Payers, meanwhile, are still waiting for a price tag: Moderna has signaled list pricing in the high five figures per series, a figure that will determine whether personalized mRNA moves from academic centers into the community oncology setting where most adjuvant melanoma is delivered.

Derm Field will track the Oncodaily feature for added clinical detail and any direct Elsner quotation once the full piece is parsed.